IB001
IB001 is a humanized anti-BAG3 antibody that inhibits BAG3, with a KD value of 14.4 nM for human BAG3. IB001 blocks BAG3-dependent monocyte/macrophage activation, interferes with the interaction between BAG3 and IFITM-2, and disrupts tumor microenvironment signaling pathways. IB001 inhibits tumor growth, reduces α-SMA-positive fibroblasts, and blocks BAG3-dependent IL-6 release. IB001 accumulates in a time-dependent manner in pancreatic ductal adenocarcinoma tumors. IB001 can be used for research related to pancreatic ductal adenocarcinoma.
For research use only. We do not sell to patients.
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
- Purity & Documentation
- References
-
Help & FAQs
Biological Activity
Human
|
HSP70 |
IB001 (BAG3-H2L4) binds to purified recombinant human BAG3 protein with a Kd of 14.4 nM[1].
IB001 inhibits binding of FITC-labeled recombinant human BAG3 to murine J774A.1 macrophage cells[1].
IB001 (9.37-300 μg/mL; 16 h) dose-dependently inhibits recombinant human BAG3-induced IL-6 production by isolated human CD14+ monocytes[1].
IB001 (200 μg/mL; 16 h) significantly inhibits PANC-1 pancreatic cancer cell conditioned medium-induced IL-6 production by isolated human CD14+ monocytes[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
IB001 (20 mg/kg; daily; 7 days) does not induce cardiotoxicity in 6-month-old athymic nude-Foxn1 nu/nu mice after 7 days of daily treatment[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:CD-1 nu/nu (female, 6 weeks old, injected with MIA PaCa-2 cells)[1]
-
Dosage:20 mg/kg
-
Administration:every 48 h; twice a week
-
Result:Achieved significant tumor growth inhibition, with final tumor volume reaching ~400% of initial volume compared to ~1000% in vehicle controls.
Reduced α-SMA-positive fibroblast area in tumor tissue from ~3.5% in vehicle-treated mice to <0.5%.
-
Animal Model:Athymic nude-Foxn1 nu/nu (6 months old)[1]
-
Dosage:20 mg/kg
-
Administration:daily; 7 days
-
Result:Showed no adverse effect on ejection fraction, shortening fraction, or strain percentage.
O95817
BAG3
Unconjugated
The product can be reconstituted/diluted with sterile PBS or saline.
-
Product Image
ELISA, FACS, Functional assay
Chemical Information
-
Synonyms
BAG3-H2L4
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
IB001 Related Classifications
HY-P992379 Related Classifications
Powered by Bioz